ArticleNPJ digital medicine2026
Evaluating large language models for pharmacotherapy simulations: a mixed-methods study.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Simulation-based learning is essential in clinical pharmacy education but requires substantial faculty resources that limit scalability. Large language models (LLMs) offer promise for generating scalable simulations, yet their pedagogical rigor and clinical reliability remain unclear. In a mixed-methods, counterbalanced evaluation study, PharmD students (n = 104) engaged with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML) cases, conditions requiring complex longitudinal management yet sharing semantic similarity, generated by four LLMs using expert-guided meta-prompts. Expert panels evaluated sessions across clinical authenticity, instructional design, and clinical reasoning; students completed satisfaction surveys. Of 103 sessions, 53 (51.5%) met passing criteria across all domains. Clinical accuracy and safety emerged as the limiting domain (58.3%) compared to clinical reasoning (81.6%) and instructional design (82.5%). CML sessions outperformed AML sessions (62.3% vs 40.0%; p = 0.031). Platform success rates ranged from 34.5% to 62.1%. Error analysis revealed guideline misalignment, pharmacotherapeutic inaccuracies, fabricated evidence, and cross-condition therapeutic recommendations occurring exclusively in AML sessions. Students favored LLMs over traditional methods (49.8% vs 30.0%); however, we did not detect statistically significant alignment between student satisfaction and expert-assessed quality. Sessions more frequently met criteria for instructional design and clinical reasoning than for pharmacotherapeutic accuracy and guideline alignment. Expert oversight with platform-specific and disease-specific validation remains essential for safe educational deployment, and effectiveness trials assessing objective learning outcomes represent necessary subsequent work.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.